Number of people treated with ivermectin from 1993–2014 in Obongi onchocerciasis focus.

<p>Number of people treated with ivermectin from 1993–2014 in Obongi onchocerciasis focus.</p

Showing results of children <10 years screened with Ov16 ELISA in Obongi focus.

<p>Showing results of children <10 years screened with Ov16 ELISA in Obongi focus.</p

Human landing catches at Kochi Boma and Lomunga sites in Obongi focus, northwestern Uganda.

<p>Human landing catches at Kochi Boma and Lomunga sites in Obongi focus, northwestern Uganda.</p

Microfilariae and nodule prevalence in Obongi focus, northwestern Uganda in 2012.

<p>Microfilariae and nodule prevalence in Obongi focus, northwestern Uganda in 2012.</p

Impact assessments of lymphatic filariasis (elephantiasis) from 2006 to 2015 in Moyo district.

<p>Impact assessments of lymphatic filariasis (elephantiasis) from 2006 to 2015 in Moyo district.</p

The interruption of <i>Onchocerca volvulus</i> and <i>Wuchereria bancrofti</i> transmission by integrated chemotherapy in the Obongi focus, North Western Uganda

<div><p>Intervention</p><p>Few studies have documented the interruption of onchocerciasis and Lymphatic Filariasis (LF) by integrated chemotherapy in Uganda. The study describes the interruption of transmission of the two diseases co-endemic in Obongi focus, north western Uganda. Base line data for Onchocerciasis and LF were collected in 1994 and 2006, respectively. Annual mass drug administration for onchocerciasis (Ivermectin) and Lymphatic Filariasis (Ivermectin + albendazole) was conducted for 20 and 6 years, respectively. Thereafter, assessments by skin snip, larval searches in rivers and human landing catches were performed. Children <10 years were screened for IgG4 antibodies using Ov16 ELISA technique in 2013. LF Pre-TAS and TAS1 were conducted in sentinel sites. ITN coverage and utilization for the implementation unit was also reported.</p><p>Intervention coverage</p><p>Onchocerciasis treatment coverage was <80% but improved with the introduction of CDTI in 1999. While for LF, effective coverage of >65% was achieved in the six treatment rounds. Household ownership of ITN’s and utilization was 96% and 72.4%., respectively.</p><p>Impact</p><p>Parasitological examinations conducted for onchocerciasis among 807 adults and children, revealed a reduction in mf prevalence from 58% in 1994 to 0% in 2012. Entomological monitoring conducted at the two sites had no single <i>Simulium damnosum</i> fly caught. Serological analysis using Ov16 ELISA for onchocerciasis revealed that out of the 3,308 children <10 years old screened in 2013, only 3/3308 (0.091%) positive cases were detected. All Ov16 positive children were negative when tested for patent infection by skin snip PCR. A reduction in LF microfilaria prevalence from 2.5% (n = 13/522) in 2006 to 0.0% (n = 602) in 2014 was observed. LF TAS1 conducted in 2015 among 1,532 children 6–7 years, all were negative for antigens of <i>W</i>. <i>bancrofti</i>.</p><p>Conclusion</p><p>The results concluded that interruption of onchocerciasis and LF has been achieved.</p></div

Percent treatment coverage for lymphatic filariasis from 2006–2016 in Moyo districts.

<p>Percent treatment coverage for lymphatic filariasis from 2006–2016 in Moyo districts.</p